68 related articles for article (PubMed ID: 36455758)
1. Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer.
Tang B; Wang Y; Xu W; Zhu J; Weng Q; Chen W; Fang S; Yang Y; Qiu R; Chen M; Mao W; Xu M; Zhao Z; Cai S; Zhang H; Ji J
Cancer Lett; 2023 Feb; 554():216021. PubMed ID: 36455758
[TBL] [Abstract][Full Text] [Related]
2. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
3. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.
Zhou Q; Liang J; Yang T; Liu J; Li B; Li Y; Fan Z; Wang W; Chen W; Yuan S; Xu M; Xu Q; Luan Z; Xia Z; Zhou P; Huang Y; Chen L
EMBO Mol Med; 2022 Jan; 14(1):e14502. PubMed ID: 34898004
[TBL] [Abstract][Full Text] [Related]
5. Shedding light on macrophage immunotherapy in lung cancer.
Ma H; Zhang Z; Hu Q; Chen H; Wu G; Zhou Y; Xue Q
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8143-8152. PubMed ID: 37052632
[TBL] [Abstract][Full Text] [Related]
6. PURPL Promotes M2 Macrophage Polarization in Lung Cancer by Regulating RBM4/xCT Signaling.
Guo J; Gong C; Wang H
Crit Rev Eukaryot Gene Expr; 2024; 34(5):59-68. PubMed ID: 38842204
[TBL] [Abstract][Full Text] [Related]
7. VISTA deficiency exerts anti-tumor effects in breast cancer through regulating macrophage polarization.
Jin S; Liu W; He X; Zhang Y; Chen W; Wu Y; Liu J
Int Immunopharmacol; 2024 May; 136():112365. PubMed ID: 38820964
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors.
Liu Y; Qi X; Li G; Sowa G
Sci Rep; 2019 Dec; 9(1):18970. PubMed ID: 31831780
[TBL] [Abstract][Full Text] [Related]
9. Lung tumor growth is stimulated in IFN-gamma-/- mice and inhibited in IL-4Ralpha-/- mice.
Redente EF; Dwyer-Nield LD; Barrett BS; Riches DW; Malkinson AM
Anticancer Res; 2009 Dec; 29(12):5095-101. PubMed ID: 20044622
[TBL] [Abstract][Full Text] [Related]
10. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance.
Zhou J; Lyu N; Wang Q; Yang M; Kimchi ET; Cheng K; Joshi T; Tukuli AR; Staveley-O'Carroll KF; Li G
Cancer Lett; 2023 Dec; 578():216457. PubMed ID: 37865162
[TBL] [Abstract][Full Text] [Related]
11. The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy.
Wang C; Gao Q; Wu J; Lu M; Wang J; Ma T
Adv Biol (Weinh); 2024 Apr; ():e2400119. PubMed ID: 38684453
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages affect the treatment of lung cancer.
Yu Z; Zou J; Xu F
Heliyon; 2024 Apr; 10(7):e29332. PubMed ID: 38623256
[TBL] [Abstract][Full Text] [Related]
13. Compartmentalized role of xCT in supporting pancreatic tumor growth, inflammation and mood disturbance in mice.
Lara O; Janssen P; Mambretti M; De Pauw L; Ates G; Mackens L; De Munck J; Walckiers J; Pan Z; Beckers P; Espinet E; Sato H; De Ridder M; Marks DL; Barbé K; Aerts JL; Hermans E; Rooman I; Massie A
Brain Behav Immun; 2024 May; 118():275-286. PubMed ID: 38447884
[TBL] [Abstract][Full Text] [Related]
14. Lanosterol synthase deficiency promotes tumor progression by orchestrating PDL1-dependent tumor immunosuppressive microenvironment.
Gao Y; Zhao K; Huang Y; Zhang D; Luo N; Peng X; Yang F; Xiao W; Wang M; Shi R; Miao H
MedComm (2020); 2024 Apr; 5(4):e528. PubMed ID: 38606362
[TBL] [Abstract][Full Text] [Related]
15. TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC.
Tang B; Wang Y; Zhu J; Song J; Fang S; Weng Q; Yang Y; Tu J; Zhao Z; Chen M; Xu M; Chen W; Ji J
Biol Proced Online; 2023 May; 25(1):13. PubMed ID: 37208604
[TBL] [Abstract][Full Text] [Related]
16. Identifying a novel cuproptosis-related necroptosis gene subtype-related signature for predicting the prognosis, tumor microenvironment, and immunotherapy of hepatocellular carcinoma.
Shi Y; Qiu P; Zhao K; Li X; Feng Y; Deng Z; Wang J
Front Mol Biosci; 2023; 10():1165243. PubMed ID: 37287752
[No Abstract] [Full Text] [Related]
17. Effect of tumor microenvironment on ferroptosis: inhibition or promotion.
Xia Z; Quan Y
Front Oncol; 2023; 13():1155511. PubMed ID: 37213276
[TBL] [Abstract][Full Text] [Related]
18. WIPI2 enhances the vulnerability of colorectal cancer cells to erastin via bioinformatics analysis and experimental verification.
Yu L; Luo Y; Ding X; Tang M; Gao H; Zhang R; Chen M; Liu Y; Chen Q; Ouyang Y; Wang X; Zhen H
Front Oncol; 2023; 13():1146617. PubMed ID: 37207153
[TBL] [Abstract][Full Text] [Related]
19. Machine learning-based construction of a ferroptosis and necroptosis associated lncRNA signature for predicting prognosis and immunotherapy response in hepatocellular cancer.
Zhao L; You Z; Bai Z; Xie J
Front Oncol; 2023; 13():1171878. PubMed ID: 37152064
[TBL] [Abstract][Full Text] [Related]
20. SLC7A11-associated ferroptosis in acute injury diseases: mechanisms and strategies.
Li P; Yu J; Huang F; Zhu YY; Chen DD; Zhang ZX; Xie ZC; Liu ZY; Hou Q; Xie N; Peng TH; Chen X; Li L; Xie W
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4386-4398. PubMed ID: 37259719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
